Asthma biologics show surprising heart benefits. A new study found that adults with severe asthma on biologic therapies had significantly lower risks of heart attack, stroke, heart failure, and death compared to those on other treatments. Researchers say the findings add a compelling cardiovascular dimension to how we evaluate these drugs.
Biologics are already known for reducing asthma flare-ups and cutting down on steroid use — but a new study suggests they may also be doing something remarkable for the heart. Presented at the CHEST Annual Meeting, the propensity score-matched analysis of nearly 20,000 adults with severe asthma found that those on biologic therapy had significantly lower risks of major adverse cardiovascular events (MACE) compared to matched controls on other treatments.
The findings are notable because severe asthma is itself a cardiovascular risk factor — chronic systemic inflammation and repeated oral corticosteroid use both take a toll on the heart. Researchers believe biologics may help by reducing exacerbations and steroid exposure, though they caution the results are observational and hypothesis-generating.
By the Numbers:
Why it matters: These findings suggest that when clinicians evaluate biologic therapy for severe asthma, cardiovascular outcomes deserve a seat at the table — especially for patients who already carry significant heart disease risk.
